Pharmacogenetics in cancer etiology and chemotherapy

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1025-1030

  Boddy, Alan V ^a   Ratain, Mark J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALDEHYDE DEHYDROGENASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; ETOPOSIDE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; MERCAPTOPURINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIFEDIPINE; PACLITAXEL; THIOPURINE METHYLTRANSFERASE; VERAPAMIL;

DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ALCOHOL DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROURACIL DEHYDROGENASE (NADP); GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; NEOPLASMS; OXIDOREDUCTASES; PHARMACOGENETICS;

EID: 0030814080     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (106)

1. Kalow, W. Pharmacogenetics: its biological roots and the medical challenge. Clin. Pharmacol. Ther., 54: 235-241, 1993.
2. Propping, P., and Nothen, M. M. Genetic variation of CNS receptors: a new perspective for pharmacogenetics. Pharmacogenetics, 5: 318-325, 1995.
3. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet, ii: 584-586, 1977.
4. Nebert, D. W., McKinnon, R. A., and Puga, A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol., 15: 273-280, 1996.
5. Smith, G., Stanley, L. A., Sim, E., Strange, R. C., and Wolf, C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv., 25: 27-65, 1995.
6. Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tornling, G., and Rannug, A. Genetic susceptibility to lung-cancer with special emphasis on CYP1A1 and GSTm1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis (Lond.), 15: 1785-1790, 1994.
7. Uematsu, F., Ikawa, S., Kikuchi, H., Sagami, I., Kanamaru, R., Abe, R., Satoh, K., Motomiya, M., and Watanabe, M. Restriction fragment-length polymorphism of the human CYP2E1 (cytochrome-P450IIE1) gene and susceptibility to lung-cancer: possible relevance to low smoking exposure. Pharmacogenetics, 4: 58-63, 1994.
8. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 311: 169-170, 1984.
9. Brockmoller, J., Kerb, R., Drakoulis, N., Staffeldt, B., and Roots, I. Glutathione-S-transferase-m1 and its variant-A and variant-B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res., 54: 4103-4111, 1994.
10. Bell, D. A., Stephens, E. A., Castranio, T., Umbach, D. M., Watson, M., Deakin, M., Elder, J., Hendrickse, C., Duncan, H., and Strange, R. C. Polyadenylation polymorphism in the acetyltransferase-1 gene (NAT1) increases risk of colorectal cancer. Cancer Res., 55: 3537-3542, 1995.
11. Ilett, K. F., Detchon, P., Ingram, D. M., and Castleden, W. M. Acetylation phenotype is not associated with breast cancer. Cancer Res., 50: 6649-6651, 1990.
12. Duche, J-C., Joanne, C., Barre, J., de Cremoux, H., Dalphin, J. C., Depierre, A., Brochard, P., Tillement, J. P., and Bechtel, P. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br. J. Clin. Pharmacol., 31: 533-536, 1991.
13. Vineis, P., and Caporaso, N. The analysis of restriction fragment length polymorphism in human cancer: a review from an epidemiological perspective. Int. J. Cancer, 47: 26-30, 1991.
14. Romkes, M., Chern, H. D., Lesnick, T. G., Becich, M. J., Persad, R., Smith, P., and Branch, R. A. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Carcinogenesis (Lond.), 17: 1057-1062, 1996.
15. Vineis, P., and Schulet, P. A. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J. Clin. Epidemiol., 48: 189-197, 1995.
16. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol., 43: 329-339, 1992.
17. Lennard, L., Lilleyman, J. S., van Loon, J., and Weinshilboum, R. M. Genetic variation in response to 6-mercaptopurine for childhood acute leukaemia. Lancet, 336: 225-229, 1990.
18. Lee, D., Szumlanski, C., Houtman, J., Honchel, R., and Rojas, K. Thiopurine methyltransferase pharmacogenetics: cloning of human liver cDNA and a processed pseudogene on human chromosome 18Q21.1. Drug Metab. Disp., 23: 398-405, 1995.
19. Krynetski, E. Y., Tai, H. L., Yates, C. R., Fessing, C. R., Loennechen, T., Schuetz, J. D., Relling, M. V., and Evans, W. E. Genetic-polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics, 6: 279-290, 1996.
20. McLeod, H. L., Lin, J. S., Scott, E. P., Pui, C. H., and Evans, W. E. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther., 55: 15-20, 1994.
21. McLeod, H. L., Krynetski, E. Y., and Evans, W. E. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics, 5: 281-286, 1995.
22. Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., and Roberts, W. M. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr., 119: 985-989, 1991.
23. Lennard, L., van Loon, J. A., and Weinshilboum, R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther., 46: 149-154, 1989.
24. Schmiegelow, K., Schroder, H., Gustafsson, G., Kristinsson, J., Glomstein, A., Salmi, T., and Wranne, L. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J. Clin. Oncol., 13: 345-351, 1995.
25. Lennard, L., Hale, H. P., and Lilleyman, J. S. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br. J. Clin. Pharmacol., 36: 277-284, 1993.
26. Traut, T. W., and Loechel, S. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. Biochemistry, 23: 2533-2539, 1984.
27. Tuchman, M., Stoeckeler, J. S., Kiang, D. T., O'Dea, R. F., Rammaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyrimidimuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
28. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest., 81: 47-51, 1988.
29. Harris, B. E., Carpenter, J. T., and Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
30. Takai, S., Gernandez-Salguero, P., Kimura, S., Gonzalez, F. J., and Yamada, K. Assignment of the human dihydropyrimidine dehydrogenase gene (DYPD) to chromosome region 1p22 by fluorescence in situ hybridisation. Genomics, 24: 613-614, 1994.
31. Meinsma, R., Fernandez-Salguero, P., van Kulenberg, A. B., van Gennip, A. H., and Gonzalez, F. J. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol., 14: 1-6, 1995.
32. Tatsumi, K., Yamauchi, T., Kiyons, K., Kislui, K., Yangihara, Y., Imaoka, T., Kawaguchi, T., and Kuko, M. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J. Biochem. (Tokyo), 114: 912-918, 1993.
33. Baccanari, D. P., Davis, S. T., Knick, V. C., and Spector, T. 5-Ethynyluracil (776c85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc. Natl. Acad. Sci. USA, 90: 11064-11068, 1993.
34. Naguib, F. N., Hao, S. N., and el Kouni, M. H. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res., 54: 5166-5170, 1994.
35. Adjei, A. A., Doucett, M., Spector, T., Khor, S. P., Sartorius, S. E., Bowling, M. K., Baker, S., Donehower, R. C., Grochow, L. B., Hohneker, J., and Rowinsky, E. K. 5-Ethinyluracil (776C85), an inhibitor of dihydropyrimidine dehydrogenase, permits reliable oral dosing of 5-fluorouracil and prolongs its half-life. Proc. Am. Soc. Clin. Oncol., 14: 1478, 1995.
36. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelsmansundberg, M., Ishizaki, T., Jacqzaigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., and Zanger, U. M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6: 193-201, 1996.
37. Lennard, M. S. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol. Toxicol., 67: 273-283, 1990.
38. Relling, M. V., Evans, W. E., Fonne-Pfister, R., and Meyer, U. A. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res., 49: 68-71, 1989.
39. Kupfer, A., Desmond, P., Patwardhan, R., Schenker, S., and Branch, R. A. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin. Pharmacol. Ther., 35: 33-39, 1984.
40. Goldstein, J. A., and Demorais, S. M. F. Biochemistry and molecular biology of the CYP2C subfamily. Pharmacogenetics, 4: 285-299, 1994.
41. Romkes, M., Faletto, M. B., Raucy, J. L., and Goldstein, J. A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30: 3247-3255, 1991.
42. Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L., Goldstein, J. A., Woosley, R. L., and Flockhart, D. A. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther., 57: 662-669, 1995.
43. Sullivanklose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J., and Goldstein, J. A. The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6: 341-349, 1996.
44. Busse, D., Cosme, J., Beaune, P., Kroemer, H. K., and Eichelbaum, M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naun.-Schmied. Arch. Pharmacol., 353: 116-121, 1995.
45. Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin. H. V., and Korzekwa, K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33: 6450-6455, 1994.
46. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
47. Walker, D., Flinois, J-P., Monkman, S. C., Beloc, C., Boddy, A. V., Cholerton, S., Daly, A. K., Lind, M. J., Pearson, A. D. J., Beaune, P. H., and Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol., 47: 1157-1163, 1994.
48. Relling, M. V., Evans, R., Dass, C., Desiderio, D. M., and Nemec, J. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther., 261: 491-496, 1992.
49. Harris, J. W., Rahman, A., Kim, B-R., Guengerich, F. P., and Collins, J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
50. Zhou, X-J., Zhou-Pan, X-R., Gauthier, T., Placici, M., Maurel, P., and Rahmani, R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem. Pharmacol., 45: 853-861, 1993.
51. Fahr, A. Cyclosporine clinical pharmacokinetics. Clin. Pharmacokinet., 24: 472-495, 1993.
52. Kroemer, H. K., Gautier, J. C., Beaune, P., Henderson, C., Wolf, C. R., and Eichelbaum, M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naun.-Schmied. Arch. Pharmacol., 348: 332-337, 1993.
53. Boddy, A. V., Cole, M., Pearson, A. D. J., and Idle, J. R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother. Pharmacol., 36: 53-60, 1995.
54. Kurowski, V., and Wagner, T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol., 33: 36-42, 1993.
55. Chen, T-L., Passos-Coelho, J. L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res., 55: 810-816, 1995.
56. Kleinbloesem, C. H., van Brummelen, P., Faber, H., Danhof, M., Vermeulen, N. P. E., and Breimer, D. D. Variability in nifedipine kinetics and dynamics: a new oxidation polymorphism in man. Biochem. Pharmacol., 33: 3721-3724, 1984.
57. Horsmans, Y., Desager, J. P., and Harvengt, C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol. Toxicol., 71: 258-261, 1992.
58. Schuetz, J. D., Beach, D. L., and Guzelian, P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 4: 11-20, 1994.
59. Schuetz, E. G., Schuetz, J. D., Grogan, W. M., Naray-Fejes-Toth, A., Fejes-Toth, G., Raucy, J., Guzelian, P., Gionela, K., and Watlington, C. O. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch. Biochem. Biophys., 294: 206-214, 1992.
60. Forrester, L. M., Henderson, C. J., Glancey, M. J., Back, D. J., Park, B. K., Ball, S. E., Kitteringham, N. R., McLaren, A. W., Miles, J. S., Skett, P., and Wolf, C. R. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J., 281: 359-368, 1992.
61. Hakkola, J., Pasanen, M., Purkunen, R., Saarikoski, S., Pelkonen, O., Maenpaa, J., Rane, A., and Raunio, H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem. Pharmacol., 48: 59-64, 1994.
62. Walker, D., Ranu, H. K., Pearson, A. D. J., and Idle, J. R. Cytochrome P450 CYP3A5 makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc. Am. Soc. Cancer Res., 36: 373, 1995.
63. Skinner, R., Pearson, A. D. J., Price, L., Wyllie, R. A., Coulthard, M. G., and Craft, A. W. Ifosfamide nephrotoxicity in children: risk factors and the long term outcome. Med. Pediatr. Oncol. 23: 265, 1994.
64. Murray, G. I., Foster, C. O., Barnes, T. S., Weaver, R. J., Ewen, S. W. B., Melvin, W. T., and Burke, M. D. Expression of cytochrome-P450IA in breast cancer. Br. J. Cancer, 63: 1021-1023, 1991.
65. Huang, Z. Q., Fasco, M. J., Figge, H. L., Keyomarsi, K., and Kaminsky, L. S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Disp., 24: 899-905, 1996.
66. Kivisto, K. T., Griese, E. U., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P., and Kroemer, H. K. Expression of cytochrome-P-450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors. Naun.-Schmied. Arch. Pharmacol., 353: 207-212, 1996.
67. Albin, N., Massaad, L., Toussaint, C., Mathieu, M. C., Morizet, J., Parise, O., Gouyette, A., and Chabot, G. G. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res., 53: 3541-3546, 1993.
68. Dockham, P. A., Lee, M-O., and Sladek, N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol., 43: 2453-2469, 1992.
69. Bunting, K. D., and Townsend, A. J. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anticancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J. Biol. Chem., 271: 1184-1189, 1996.
70. Sreerama, L., and Sladek, N. E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol., 45: 2487-2505, 1993.
71. Hadidi, A-H. F. A., Coulter, C. E. A., and Idle, J. R. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res., 48: 5167-5171, 1988.
72. Boddy, A. V., Furtun, Y., Sardas, S., Sardas, O., and Idle, J. R. Individual variation in the activation and inactivation metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst., 84: 1744-1748, 1992.
73. Yule, S. M., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M., Pearson, A. D. J., and Idle, J. R. Cyclophosphamide metabolism in children. Cancer Res., 55: 803-809, 1995.
74. Boddy, A. V., Yule, S. M., Wyllie, R., Price, L., Pearson, A. D. J., and Idle, J. R. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother. Pharmacol., 38: 147-154, 1996.
75. Yoshida, A., and Chen, S-H. Restriction fragment length polymorphism of human aldehyde dehydrogenase 1 and aldehyde dehydrogenase 2 loci. Hum. Genet., 83: 204-204, 1989.
76. Waxman, D. J. Glutathione S-transferases - role in alkylating agent resistance and possible target for modulation chemotherapy: a review. Cancer Res., 50: 6449-6454, 1990.
77. Dirven, H. A. A. M., van Ommen, B., and van Bladeren, P. J. Involvement of human glutathione-S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res., 54: 6215-6220, 1994.
78. Lautier, D., Canitrot, Y., Deeley, R. G., and Cole, S. P. C. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol., 52: 967-977, 1996.
79. Board, P. G., Coggan, M., Johnston, P., Ross, V., Suzuki, T., and Webb, G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol. Ther., 48: 357-369, 1990.
80. Hall, A. G., Autzen, P., Cattan, A. R., Malcolm, A. J., Cole, M., Kernahan, J., and Reid, M. M. Expression of μ class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res., 54: 5251-5254, 1994.
81. Hall, A. G., Matheson, E., Kearns, P. R., Kernahan, J., and Reid, M. M. Expression of mu class glutathione S-transferase in childhood acute lymphoblastic leukaemia. Proc. Am. Soc. Cancer Res., 36: 315, 1995.
82. Schroder, K. R., Wiebel, F. A., Reich, S., Dannappel, D., Bolt, H. M., and Hallier, E. Glutathione-S-transferase (GST) theta polymorphism influences background SCE rate. Arch. Toxicol. 69: 505-507, 1995.
83. Grant, D. M., Blum, M., Beer, M., and Meyer, U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol., 39: 184-191, 1991.
84. Weber, W. W. The acetylator genes and drug response. New York: Oxford University Press, 1987.
85. Vatsis, K. P., and Weber, W. W. Structural heterogeneity of caucasian N-acetyltransferase at the NAT1 locus. Arch. Biochem. Biophys., 301: 71-76, 1993.
86. Legha, S. S., Ring, S., Raber, M., Felder, T. B., Newman, R. A., and Krakoft, I. H. Phase I clinical investigation of benzisoquinolinedione. Cancer Treat. Rep., 71: 1165-1169, 1987.
87. Leiby, J. M., Malspeis, L., Staubuo, A. E., Kraut, E. H., and Grever, M. R. Amonafide (NSC 308847): a clinical Phase I study of two schedules of administration. Proc. Am. Assoc. Cancer Res., 29: 278, 1988.
88. Ratain, M. J., Rosner, G., Allen, S. L., Costanza, M., Van Echo, D. A., Henderson, I. C. and Schilsky, R. L. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J. Clin. Oncol., 13: 741-747, 1995.
89. Ratain, M. J., Mick, R., Berezin, F., Janisch, L., Schilsky, R. L., Vogelzang, N. J., and Lane, L. B. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res., 53: 2304-2308, 1993.
90. Ratain, M. J., Mick, R., Janisch, L., Berezin, F., Schilsky, R. I., Vogelzang, N. J., and Kut, M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics, 6: 93-101, 1996.
91. Ritter, J. K., Crawford, J. M., and Owens, I. S. Cloning of two human liver bilirubin UGT cDNAs with expression in COS-1 cells. J. Biol. Chem., 206: 1043-1047, 1991.
92. van Es, H. H. G., Goldhoorn, B., Paul-Abrahamse, P., Oude Elferink, R. P. J., and Jansen, P. L. M. Immunochemical characterization of UDP-glucuronosyltransferase in four patients with the Crigler-Najjar type I syndrome. J. Clin. Invest., 85: 1199-1205, 1990.
93. Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Oude Elferink, R. P. J., and Chowdhury, N. R. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med., 333: 1171-1175, 1995.
94. Monagham, G., Ryan, M., Seddon, R., Hume, R., and Burchell, B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 347: 578-581, 1996.
95. Robert, J., David, M., and Granger, C. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemother. Pharmacol., 27: 147-150, 1990.
96. Schilsky, R. L., Ratain, M. J., Janisch, L., Vogelzang, N. J., Lucas, V. S., Ravitch, J., Hohneker, J. A., Clendeninn, N. J., and Tittle, R. L. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother. Pharmacol., 31: 283-288, 1993.
97. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Yokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans; correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
98. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., and Ratain, M. J. A pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan (CPT-11) in cancer patients. J. Clin. Oncol., 15: 1502-1510, 1997.
99. Iyer, L., King, C., Tephly, T., and Ratain, M. J. UGT isoform 1.1 glucuronidates SN-38, the active metabolite of irinotecan. Proc. Am. Soc. Clin. Oncol., 16: 201a, 1997.
100. 6-alkylguanine-DNA alkyltransferase. Prog. Nucl. Acid Res. Mol. Biol., 51: 167-223, 1995.
101. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5386-5372, 1990.
102. 6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis (Lond.), 16: 2441-2445, 1995.
103. 6-benzylguanine. Cancer Res., 56: 5571-5575, 1996.
104. Beall, H. D., Mulcahy, R. T., Siegel, D., Traver, R. D., Gibson, N. W., and Rodd, D. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res., 54: 3196-3201, 1994.
105. Traver, R. D., Siegel, D., Beall, H. D., Philips, R. M., Gibson, N. W., Franklin, W. A., and Ross, D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer, 75: 69-75, 1997.
106. Guerney, H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol., 14: 2590-2611, 1996.